DataMeds AI, Inc. — Form 8-K
Filed August 18, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
DataMeds AI (market cap ~$27.1M) raised $6.5M in June 2026 and reported Q2 2026 revenues of $1.779M (14% sequential growth), but posted a net operating loss of $18.363M in Q2 2026 vs. $6.672M in Q2 2025, driven by $8.881M debt extinguishment loss and other charges. The company executed a 1:50 reverse stock split in May 2026 to address NASDAQ delisting risk, completed a corporate rebranding to DataMeds AI with ticker change to MEDS, and is pursuing a pending multi-party transaction with Datavault AI, Scilex, EOS Technology, and HealthBridge to consolidate IP and launch a Health Lives Here app targeting GLP-1 patients via NFL Alumni Health partnership by September 2026. Shareholders representing ~49% of shares entered 90-day lock-up agreements.
Why this rating
At $27.1M market cap, the $6.5M funding and strategic deals are material (24% of cap), but massive Q2 loss, deteriorating cash burn, reverse split, delisting pressure, and negative equity ($19.5M deficit) signal distress. Revenue growth is outweighed by operational collapse.
See more from August 18, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.